Real-world first-line treatment of patients with BRAF^V600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study.

ABSTRACT:

Background

BRAF^V600E mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab in first line. However, an unmet need remains for more effective treatments for these patients.

Patients and methods

CAPSTAN CRC is a European, retrospective, multicenter, observational study evaluating real-world treatment practices for patients with BRAF^V600E-mutant mCRC treated between 1 January 2016 and 31 January 2020. The primary objective was to describe first-line treatment patterns. Secondary objectives included describing baseline demographics, mutational testing procedures, treatment effectiveness, and safety.

Results</

SUBMITTER: Martinelli E 

PROVIDER: S-EPMC9832736 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature